Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
Department of Medicine, Uniformed Services University, Bethesda, Maryland 20814, USA. pomalley@usuhs.edu
Patrick G
PG
O'Malley
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D057186:Comparative Effectiveness Research; D003930:Diabetic Retinopathy / Q000150:complications* / Q000188:drug therapy*; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology*; D056687:Off-Label Use; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000191:economics / Q000627:therapeutic use; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; C495058:pegaptanib; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab